Attention investors who purchased shares of Indivior PLC between March 10, 2015 and April 9, 2019:
Rigrodsky & Long is investigating claims brought in a securities fraud class action complaint against Indivior PLC ("Indivior") concerning whether Indivior and certain of the Company's directors and/or officers made materially false and misleading statements and failed to disclose materially adverse facts during the period March 10, 2015 and April 9, 2019, inclusive (the "Class Period"), concerning Indivior's business, operations and prospects. These misrepresentations and omissions artificially inflated the price of Indivior's stock throughout the Class Period.
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of Indivior PLC (“Indivior” or the “Company”) (OTC PINK: INVVY) between March 10, 2015 and April 9, 2019, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
f you purchased shares of Indivior during the Class Period and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Seth D. Rigrodsky or Timothy J. MacFall at Rigrodsky & Long, P.A., 300 Delaware Avenue, Suite 1220, Wilmington, DE 19801, by telephone at (888) 969-4242, by e-mail at firstname.lastname@example.org, or at http://rigrodskylong.com/contact-us/.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) Indivior and its executives engaged in an illicit nationwide scheme to increase prescriptions of Suboxone Film; (2) Indivior illegally obtained billions of dollars in revenue from Suboxone Film prescriptions by deceiving health care providers and health care benefit programs; (3) as a result of the aforementioned misconduct, Indivior would face felony charges; and (4) due to the foregoing, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that a federal grand jury had indicted Indivior “for engaging in an illicit nationwide scheme to increase prescriptions of Suboxone Film, an opioid drug used in the treatment of opioid addiction.” According to the indictment, Indivior deceived “health care providers and health care benefit programs into believing that Suboxone Film was safer, less divertible, and less abusable than other opioid-addiction treatment drugs,” acquiring billions of dollars in revenue in Suboxone Film prescriptions.
On this news, shares of Indivior declined over 66%, closing at $2.30 per share on April 10, 2019, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than June 24, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.